The fund has sold its stake in Crispr for $60.25. Reasons for the sale are below. We still believe in the valuable work in Crispr. It is more a financial decision than anything else. We will continue to monitor its progress.
- Crispr hit a target of $60.00 far quicker than the fund believed could happen.
- Other opportunities within the biosciences sector have been found.
**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.
No comments:
Post a Comment